SCHEMBL10292018

SCHEMBL10292018

CC(=O)C(N)CCCNC(=N)N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.43
NPY4R P50391 7/20 0.39
NPY1R P25929 5/20 0.39
NPY2R P49146 4/20 0.39
NPY5R Q15761 4/20 0.39
OTC P00480 1/20 0.39
ALOX15 P16050 1/20 0.39
GNAI3 P08754 1/20 0.38
GNAO1 P09471 1/20 0.38
GNAI1 P63096 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NOS3 P29474 3/20 0.38
NOS1 P29475 3/20 0.38
NOS2 P35228 3/20 0.38
DDAH1 O94760 1/20 0.37
RRM1 P23921 1/20 0.37
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8745865 1.00 DPP7 (0.43) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL8214683 1.00 DPP7 (0.43) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL16421890 0.95 DPP7 (0.46) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL10190380 0.95 DPP7 (0.46) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL13320657 0.95 DPP7 (0.46) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL13434929 0.89 ANPEP (0.37) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL12278048 0.89 ANPEP (0.37) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL8125131 0.89 ANPEP (0.37) DPP7NPY4RNPY1RNPY2RNPY5R
SCHEMBL18542868 0.87 DPP7 (0.44) DPP7OTCGNAI3GNAO1GNAI1
SCHEMBL19368710 0.87 DPP7 (0.44) DPP7OTCGNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024114953-A1 PHYLLOCHLORIN ANALOGUES SUITABLE FOR USE IN PHOTODYNAMIC THERAPY (PDT) RMW CHO GROUP LIMITED (CN) 2024-06-06 WO disclosed
US-20230295103-A1 AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI ECOLE CENTRALE DE MARSEILLE (FR) 2023-09-21 US disclosed
US-20230295103-A1 AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI ECOLE CENTRALE DE MARSEILLE (FR) 2023-09-21 US disclosed
EP-4219717-A2 EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY Sarepta Therapeutics, Inc. (US) 2023-08-02 EP disclosed
US-20230227420-A1 PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF EMPATHBIO, INC. 2023-07-20 US disclosed
US-20230183419-A1 Biodegradable Copolymers and Nanofibrous Scaffold Thereof REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-06-15 US disclosed
WO-2023094679-A1 PHOTODYNAMIC THERAPY AND DIAGNOSIS RMW CHO GROUP LIMITED (CN) 2023-06-01 WO disclosed
EP-2968080-B1 ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR SYNEDGEN INC (US) 2023-05-10 EP disclosed
WO-2023056102-A1 NOVEL PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF ATAI Life Sciences AG (DE) 2023-04-06 WO disclosed
WO-2023015533-A1 SYNTHETIC PEPTIDE, AND COSMETIC COMPOSITION OR PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 深圳市维琪医药研发有限公司 2023-02-16 WO disclosed
US-20110190395-A1 NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT PRONOVA BIOPHARMA NORGE AS (NO) 2011-08-04 US disclosed
US-20110166228-A1 COMPOSITION PRONOVA BIOPHARMA NORGE AS (NO) 2011-07-07 US disclosed
US-20100280109-A1 LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT PRONOVA BIOPHARMA NORGE AS (NO) 2010-11-04 US disclosed
US-20100266681-A1 FATTY ACID ALCOHOLS PRONOVA BIOPHARMA NORGE AS (NO) 2010-10-21 US disclosed
US-20100144655-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-06-10 US disclosed
US-20090131328-A1 FURIN INHIBITORS SMITH ROBERT E 2009-05-21 US disclosed
US-20080176807-A1 Facially amphiphilic polymers and oligomers and uses thereof MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT 2008-07-24 US disclosed
US-20080176807-A1 Facially amphiphilic polymers and oligomers and uses thereof MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT 2008-07-24 US disclosed
WO-2007038172-A2 GUANIDINIUM CARRIERS NITTO DENKO CORPORATION (JP) 2007-04-05 WO disclosed
WO-2007001926-A2 LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176807-A1 Facially amphiphilic polymers and oligomers and uses thereof TLR3, ABHD16A, ANTXR2 DPP7 1846/4885NPY4R 2483/4885NPY1R 2585/4885
US-20110166228-A1 COMPOSITION ELOVL3, FFAR3, ALOX5 DPP7 1830/4885NPY4R 217/4885NPY1R 268/4885
US-20230227420-A1 PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF COMT, PNMT, ABCB1 DPP7 314/4885NPY4R 861/4885NPY1R 1399/4885
US-20090131328-A1 FURIN INHIBITORS FURIN, PREP, TMPRSS15 DPP7 205/4885NPY4R 4051/4885NPY1R 3928/4885
US-20110190395-A1 NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT SGMS2, SGMS1, ACSS2 DPP7 1273/4885NPY4R 1552/4885NPY1R 1417/4885
US-20230295103-A1 AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI AURKA, CYP51A1, AURKC DPP7 1466/4885NPY4R 4869/4885NPY1R 4849/4885
US-20100266681-A1 FATTY ACID ALCOHOLS ALOX5, ALOX15, ALOX15B DPP7 2657/4885NPY4R 561/4885NPY1R 1220/4885
US-20100144655-A1 ORGANIC COMPOUNDS OAT, MAVS, HAVCR2 DPP7 824/4885NPY4R 3843/4885NPY1R 4188/4885
US-20100280109-A1 LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT SGMS1, SGMS2, C1S DPP7 3758/4885NPY4R 1571/4885NPY1R 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.